On Tuesday, August 25, 2020, a United Kingdom (UK)-based drug maker, AstraZeneca PLC (AstraZeneca) announced that it has started a Phase I clinical trial of its newly produced drug, known as AZD7442, to help prevent and treat COVID-19.
The trial is aimed to evaluate the safety, tolerability, and efficacy of the drug by performing a test of up to 48 healthy volunteers between the age group of 18 to 55 in the UK.The British pharmaceutical group said in a statement that the first participants have started receiving doses of AZD7442, a combination of two monoclonal antibodies (mAbs) for the trial.
Read more on toopanda.com